Jan 31, 2022

Featuring an interview with Dr Saad Zafar Usmani, including the following topics:

• Determining transplant eligibility for patients with newly diagnosed multiple myeloma (MM); treatment for transplant-eligible patients who decline transplant (0:00)
• Assessing frailty in patients with MM; underrepresentation of older patients in clinical trials (5:32)
• Selection of first-line therapy for transplant-ineligible patients with MM (10:55)
• Emerging data with daratumumab and lenalidomide/bortezomib/dexamethasone (RVd) for patients with MM; defining high-risk MM (16:56)
• Outcomes from the real-world community-based TOURMALINE US-MM6 trial evaluating ixazomib-based induction treatment (20:19)
• Efficacy and safety findings from the ENDURANCE trial comparing KRd (carfilzomib/lenalidomide/dexamethasone) to RVd (25:28)
• Optimal management of proteasome inhibitor-associated neuropathy; novel and emerging therapies for MM (28:52)
• Management of toxicities and other practical issues associated with CAR (chimeric antigen receptor) T-cell therapy for MM (34:41)

CME information and select publications